[{"address1": "650 Castro Street", "address2": "Suite 450", "city": "Mountain View", "state": "CA", "zip": "94041", "country": "United States", "phone": "650 200 0412", "website": "https://www.altoneuroscience.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.", "fullTimeEmployees": 76, "companyOfficers": [{"maxAge": 1, "name": "Dr. Amit  Etkin M.D., Ph.D.", "age": 48, "title": "Founder, Chairman of the Board, CEO & President", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 995998, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nicholas C. Smith", "age": 36, "title": "CFO & Chief Business Officer", "yearBorn": 1989, "fiscalYear": 2024, "totalPay": 680467, "exercisedValue": 0, "unexercisedValue": 217377}, {"maxAge": 1, "name": "Mr. Michael C. Hanley M.B.A.", "age": 52, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 623006, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Segal B.Sc. (Hons), BCom, CA, MSc", "age": 63, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin R. McQuade J.D.", "age": 50, "title": "General Counsel, Chief Administrative Officer & Corporate Secretary", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Savitz M.D., Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 579569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Powell", "age": 50, "title": "Chief Development Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 19.5, "open": 19.28, "dayLow": 17.08, "dayHigh": 19.49, "regularMarketPreviousClose": 19.5, "regularMarketOpen": 19.28, "regularMarketDayLow": 17.08, "regularMarketDayHigh": 19.49, "payoutRatio": 0.0, "beta": 2.851, "forwardPE": -8.832081, "volume": 171634, "regularMarketVolume": 171634, "averageVolume": 294720, "averageVolume10days": 274150, "averageDailyVolume10Day": 274150, "bid": 17.35, "ask": 17.56, "bidSize": 200, "askSize": 400, "marketCap": 547388864, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 20.908, "allTimeHigh": 24.0, "allTimeLow": 1.6, "fiftyDayAverage": 16.8272, "twoHundredDayAverage": 8.30425, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 434970816, "profitMargins": 0.0, "floatShares": 18317332, "sharesOutstanding": 31066335, "sharesShort": 2135587, "sharesShortPriorMonth": 2198907, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0687, "heldPercentInsiders": 0.06439, "heldPercentInstitutions": 0.79440004, "shortRatio": 10.92, "shortPercentOfFloat": 0.0844, "impliedSharesOutstanding": 31066335, "bookValue": 4.106, "priceToBook": 4.291281, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -62257000, "trailingEps": -2.3, "forwardEps": -1.995, "enterpriseToEbitda": -6.627, "52WeekChange": 5.2700963, "SandP52WeekChange": 0.14684999, "quoteType": "EQUITY", "currentPrice": 17.62, "targetHighPrice": 50.0, "targetLowPrice": 13.0, "targetMeanPrice": 31.25, "targetMedianPrice": 29.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 137816000, "totalCashPerShare": 4.436, "ebitda": -65632000, "totalDebt": 25398000, "quickRatio": 15.237, "currentRatio": 15.417, "debtToEquity": 22.767, "returnOnAssets": -0.24476999, "returnOnEquity": -0.45014, "freeCashflow": -36611124, "operatingCashflow": -53274000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ANRO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1706884200000, "marketState": "CLOSED", "regularMarketChangePercent": -9.64102, "regularMarketPrice": 17.62, "cryptoTradeable": false, "shortName": "Alto Neuroscience, Inc.", "postMarketChangePercent": -0.737804, "postMarketPrice": 17.49, "postMarketChange": -0.13000107, "regularMarketChange": -1.88, "regularMarketDayRange": "17.08 - 19.49", "fullExchangeName": "NYSE", "averageDailyVolume3Month": 294720, "fiftyTwoWeekLowChange": 16.02, "fiftyTwoWeekLowChangePercent": 10.0125, "fiftyTwoWeekRange": "1.6 - 20.908", "fiftyTwoWeekHighChange": -3.288, "fiftyTwoWeekHighChangePercent": -0.15726037, "fiftyTwoWeekChangePercent": 527.00964, "earningsTimestampStart": 1773927000, "earningsTimestampEnd": 1773927000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.3, "epsForward": -1.995, "fiftyDayAverageChange": 0.7928009, "fiftyDayAverageChangePercent": 0.04711425, "twoHundredDayAverageChange": 9.315751, "twoHundredDayAverageChangePercent": 1.1218053, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "corporateActions": [], "postMarketTime": 1771635301, "regularMarketTime": 1771621202, "exchange": "NYQ", "messageBoardId": "finmb_1675972978", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "Alto Neuroscience", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]